MCA
EW icon

Maryland Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Maryland Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181 Buy
+2
New +$168 ﹤0.01% 480

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Maryland Capital Advisors's EW Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in Edwards Lifesciences (EW) in Q2 2026: 2 shares worth $181. The stake represents ﹤0.01% of the portfolio and ranks #480 among its holdings.

1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Maryland Capital Advisors held 2 shares of Edwards Lifesciences worth $181 as of Q2 2026.
  • Edwards Lifesciences was a new Maryland Capital Advisors position in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #480 holding.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.